Verinata Health, Inc. Announces Agreement With Teva Pharmaceutical Industries Limited in Collaboration With MOR Institute for Medical Data to Commercialize the verifi® Prenatal Test in Israel

Published: Jul 01, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi® non-invasive prenatal test1 in Israel. The MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi® prenatal test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality. The MOR Institute, which is a wholly-owned subsidiary of Clalit Health Services, will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata.

Help employers find you! Check out all the jobs and post your resume.

Back to news